NCT06794099Completed
Study on the Applicability of CCR Criteria in Rectal Cancer
Applicability of CCR Assessment Criteria in PMMR Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Combined with Immunotherapy
Source: ClinicalTrials.gov · Last updated 27 Jan 2025
Brief summary (registry, in English)
This study aims to explore how well the usual ways of checking if rectal cancer patients are free of disease signs after treatment work for a new treatment method. The new method combines chemotherapy, radiation, and immune-boosting drugs before surgery. We know these usual ways work for the standard treatment, but we're not sure if they're good enough for this new combo treatment. We'll look at patients with a specific type of rectal cancer that doesn't respond well to just immune-boosting drugs alone. By comparing how patients treated with the new method and the old method respond, we hope to find better ways to tell if the treatment is really working, which could help improve treatment plans for these patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 177 (actual)
- First submitted
- 21 Jan 2025
- Start date
- 1 Jan 2019
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Diseases
- Colorectal cancer
- NCT number
- NCT06794099
What you commit to
- Study type: Observational
- Participants enrolled: 177
- From 1 Jan 2019 to the primary completion date, 1 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of other active malignancies;
- Having severe comorbidities, such as heart failure, severe hepatic or renal insufficiency, etc;
Other
- Lack of imaging and endoscopic examinations;
- Treatment plan does not meet the study requirements.
Who the study is looking for
- histopathologically confirmed adenocarcinoma;
- pMMR/MSS tumors;
- clinical staging of T3-T4 or any lymph node-positive T (N+);
- no evidence of distant metastasis based on radiological examinations;
- treatment with long-course chemoradiotherapy (LCRT) with or without immune checkpoint inhibitors (ICI);
- post-neoadjuvant therapy evaluation with endoscopy and pelvic MRI.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Cancer Hospital & Institute Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.